多西他赛卡铂诱导后鲁卡帕利维持治疗HRR缺陷mCRPC的2期研究
这项单臂2期试验纳入18例HRR基因致病性改变的mCRPC患者,接受4周期多西他赛+卡铂诱导化疗后鲁卡帕利维持治疗。中位随访40.3个月,全体患者中位rPFS为8.1个月,与PARP抑制剂单药历史对照相似;12例BRCA-C改变患者中位rPFS达17.7个月(p=0.05)。结论认为该策略在广泛HRR缺陷人群中未改善结局,但在BRCA-C严格选择组中结果有前景。
要点
- 诱导化疗后PARPi维持未在广泛HRR缺陷mCRPC中改善rPFS。
- BRCA-C改变患者中位rPFS 17.7个月,p=0.05。
- 单臂设计为关键局限,需进一步对照研究。
核心结论
- 铂类诱导化疗后PARP抑制剂维持未改善广泛HRR缺陷mCRPC患者的结局。
- 在BRCA-C基因改变严格选择组中结果有前景,需进一步与PARPi单药比较。
研究设计与样本
- 单臂、开放标签、研究者发起的2期试验(NCT02985021)。
- 2018至2021年单中心纳入18例HRR基因致病性改变的mCRPC患者。
主要发现
- 中位随访40.3个月(四分位距38.5-未达到),全体患者中位rPFS为8.1个月(95%CI 6.5-31.2)。
- 12例BRCA-C改变患者中位rPFS为17.7个月(95%CI 7.5-未达到;p=0.05)。
关键数值与推荐
- 诱导化疗:多西他赛60 mg/m2联合卡铂AUC 5,每21天一次,共4周期。
- 维持治疗:鲁卡帕利600 mg每日两次,直至进展或不可接受毒性。
临床怎么用
- 不支持在广泛HRR缺陷mCRPC中常规采用诱导化疗后PARPi维持策略。
- BRCA-C改变患者可能从该策略中获益,但需进一步对照研究验证。
局限性
- 单臂设计是关键局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes in comparison to a historical control cohort treated with PARPi monotherapy. METHODS: This single-arm, open-label, investigator-initiated phase 2 trial (NCT02985021) enrolled 18 patients with mCRPC with pathogenic alterations in HRR genes between 2018 and 2021 at a single center. Patients received four cycles of induction chemotherapy with docetaxel (60 mg/m2) and carboplatin (area under the curve 5) every 21 d, followed by maintenance rucaparib (600 mg twice daily) until progression or unacceptable toxicity. The primary outcome was radiographic progression-free survival (rPFS). Subsequent to study inception, multiple other studies reported alterations in genes of the BRCA complex (BRCA-C: BRCA1, BRCA2, PALB2) as most predictive of PARPi response; therefore, a post hoc analysis comparing patients with alterations in BRCA-C genes to a historical control cohort was performed. KEY FINDINGS AND LIMITATIONS: After median follow-up of 40.3 mo (interquartile range 38.5-not reached [NR]), the median rPFS for all patients was 8.1 mo (95% confidence interval [CI] 6.5-31.2), similar to a historical control cohort treated with PARPi monotherapy. Among the 12 patients with BRCA-C alterations, median rPFS was 17.7 mo (95% CI 7.5-NR; p = 0.05). A key limitation is the single-arm design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Induction platinum-based chemotherapy followed by maintenance PARPi therapy did not improve outcomes for patients with mCRPC broadly selected for HRR deficiency. However, results were promising in the more stringently selected group with BRCA-C gene alterations. Further studies comparing this approach to PARPi monotherapy are warranted.
引用
- Raychaudhuri R, Cheng HH, Gulati R, et al. Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency. Eur Urol Oncol. 2025. PMID: 40413129. doi:10.1016/j.euo.2025.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。